Eledon Pharmaceuticals
ELDN
31 hedge funds and large institutions have $17.3M invested in Eledon Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 2 closing their positions.
8% more capital invested
Capital invested by funds: $15.9M → $17.3M (+$1.35M)
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.94% less ownership
Funds ownership: 47.49% → 45.55% (-1.9%)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$63.7K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$57.2K |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$32.4K |
| 4 |
EP
Eversept Partners
New York
|
+$27.6K |
| 5 |
BlackRock
New York
|
+$3.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$448K |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$260K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$170K |
| 4 |
B
Bailard
Foster City,
California
|
-$67K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$40.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$213 | -67 | -17% |
|
|
IA
27
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
SWM
28
Spire Wealth Management
Mclean,
Virginia
| $1K | – | – | – |
|
|
B
29
Bailard
Foster City,
California
| – | -$67K | -27,413 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$914 | -287 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | -$32 | -10 | -11% |
|
|
CSS
32
Cubist Systematic Strategies
Stamford,
Connecticut
| – | +$51 | +16 | +84% |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$121 | +38 | New |
|
ELDN Hedge Fund Activity: Q3 2022 in Review
31 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2022, worth a combined $17.3M — up 8.5% from $15.9M a quarter earlier.
Fund positioning in ELDN was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 12 trimmed.
The largest buyer was CM Management, adding an estimated $63.7K. The largest seller was Ikarian Capital, cutting an estimated $448K.
- 31 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $17.3M of Eledon Pharmaceuticals stock for Q3 2022, up 8.5% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2022 was CM Management, an estimated $63.7K added.
- The largest Eledon Pharmaceuticals seller in Q3 2022 was Ikarian Capital, an estimated $448K sold.
Based on aggregated 13F filings for Q3 2022.